CN102114028A - Oral liquid for easing mucosa edema after radiotherapy of esophageal cancer - Google Patents
Oral liquid for easing mucosa edema after radiotherapy of esophageal cancer Download PDFInfo
- Publication number
- CN102114028A CN102114028A CN200910256132XA CN200910256132A CN102114028A CN 102114028 A CN102114028 A CN 102114028A CN 200910256132X A CN200910256132X A CN 200910256132XA CN 200910256132 A CN200910256132 A CN 200910256132A CN 102114028 A CN102114028 A CN 102114028A
- Authority
- CN
- China
- Prior art keywords
- radiotherapy
- oral liquid
- vitamin
- esophageal cancer
- easing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the medical technology field, in particular discloses an oral liquid for easing mucosa edema after the radiotherapy of esophageal cancer. The oral liquid is prepared by using gentamicin sulphate, dexamethasone, 2% xylocaine, 654-2 injectam vitamin B1, vitamin B2, cimetidine and physiological saline as raw materials, respectively and proportionally compounding the raw materials according to the different characteristics of the medicaments, mixing, packaging, sealing and sterilizing. The invention has the advantages of easing oesophagus mucosal congestion and edema caused by radiotherapy, lightening swallowing pain, improving the compliance of esophageal cancer patients on radiotherapy, ensuring that the radiotherapy is smoothly finished, improving the survival quality of patients, and the like. The prescription is new, and the drug preparation is prepared from low-price raw materials with wide resources and is convenient to prepare at low drug cost. Tested by patients in esophageal cancer radiotherapy in 150 clinical cases, the total effective rate reaches 98 percent without any special toxic or side effect.
Description
Technical field
The invention belongs to medicine, specifically is a kind of oral liquid that improves esophagus mucosa congestion and edema after the esophageal carcinoma radiotherapy.
Background technology
The esophageal carcinoma accounts for 2% of malignant tumor.Can adopt operative treatment than early lesion, in, epimere is than late period pathological changes or person's multirow radiotherapy that has the surgical contraindication.But radiotherapy can cause radiation esophagitis, causes the hyperemia of esophagus mucosa, edema, increases the weight of dysphagia, reduces patient's quality of life.Therefore, radiation period is implemented certain preventive measure, can avoid or reduce acute esophageal injury.Medicines such as many at present employing intravenous applications omeprazoles, curative effect is slow, and side effect is big, and has increased medical expense.
Summary of the invention
The object of the present invention is to provide a kind of oral liquid that esophagus mucosa congestion and edema curative effect is fast, side effect is little, expense is low, cure rate is high after the esophageal carcinoma radiotherapy that improves.
The objective of the invention is to realize in the following manner: a kind of oral liquid that improves esophagus mucosa congestion and edema after the esophageal carcinoma radiotherapy, this oral liquid is by gentamycin sulfate, dexamethasone, 2% lignocaine, 654-2 injection, vitamin B
1, vitamin B
12, eight kinds of western medicine compositions of cimetidine, normal saline form, it is characterized in that various injection volume percentage ratios are respectively in the oral liquid: gentamicin sulfate injection 4%～6%, dexamethasone 3%-5%, 2% lignocaine 6%～8%, 654-2 injection 1%～2%, vitamin B
16%～8%, vitamin B
126%～8%, cimetidine 2%～4%, normal saline 64%～67%.According to the characteristics of incidence of the hyperemia of esophagus mucosa, edema after the esophageal carcinoma radiotherapy, gentamycin sulfate is an aminoglycosides antibiotics, and good antibacterial action is arranged, and does not absorb or seldom absorbs at digestive tract.Dexamethasone is a glucocorticoid medicine, has pharmacological actions such as antiinflammatory, antiendotoxin, enhancing stress, can alleviate the radioactive inflammation of esophagus.Lignocaine is the local anaesthesia medicine, can suppress the effect that esophagus mucous membrane surface nerve conduction reaches topical anesthesia, and the local pain sensation is temporarily disappeared, and swallows pain symptom thereby alleviate, and increases food intake.654-2 is a periphery M cholinoceptor blocker, can remove smooth muscle spasm due to the acetylcholine, also can remove the blood capillary spasm, microcirculation improvement has relexation to the esophagus smooth muscle, and suppresses the secretion of esophagus mucous membrane surface body of gland, reduce esophagus surface mucus, be beneficial to feed.Vitamin B
1, vitamin B
12Being vitamin B group, is that carbohydrate metabolism institute is necessary.But the secretion of cimetidine gastric acid inhibitory reduces the stimulation of anti-stream gastric acid to esophagus.This prescription can improve radiotherapy and cause the hyperemia of esophagus mucosa, edema through clinical 150 routine esophageal carcinoma radiotherapy patient tests, alleviates and swallows pain, alleviates luminal stenosis, improves patient with esophageal carcinoma to radiocurable compliance, and the assurance radiotherapy is finished smoothly.Improve patient's life quality.And prescription is new, medicine configuration raw material sources are extensive, cheap, easy to make, cost of drugs is low, has no adverse reaction, and the patient easily accepts.
It is as follows to improve after the esophageal carcinoma radiotherapy oral liquid compounding method of mucosa edema: respectively with gentamicin sulfate injection 4%～6%, and dexamethasone 3%-5%, 2% lignocaine 6%～8%, 654-2 injection 1%～2%, vitamin B
16%～8%, vitamin B
126%～8%, cimetidine 2%～4%, normal saline 64%～67% dispose in proportion, and mixing, be packed as 20ml/ and prop up, sealing, sterilization treatment, standby.Gargle with eliminating cold for resuscitation water earlier before the medication, get 1 20ml of oral liquid and shake up, earlier medicinal liquid is contained in the oral cavity when advising the patient to take medicine, then an all around is rotated, more than the lasting 5min, repeatedly swallow every day 3 times more on a small quantity.
This oral liquid mucosa hyperemia, edema patient occur after being applicable to esophageal carcinoma radiotherapy, should forbid irritable food during the application, must not take food, drinks water and take other drug after the medication in 30 minutes, to above drug allergy person's forbidding.
Embodiment: with 80ml (3,200,000 U) gentamicin sulfate injection, 60ml (120mg) dexamethasone, 100ml (2g) 2% lignocaine, 20ml (100mg) 654-2 injection, 100ml (5000mg) vitamin B
1, 100ml (50mg) vitamin B
12, 40ml (8g) cimetidine, 1000ml normal saline mixing, by every 20ml coating-dividing sealing, packing, sterilization, labeling.
Claims (2)
1. improve the oral liquid of mucosa edema after the esophageal carcinoma radiotherapy, it is characterized in that by gentamycin sulfate, dexamethasone, 2% lignocaine, 654-2 injection, vitamin B
1, vitamin B
12, eight kinds of western medicine compositions of cimetidine, normal saline form.
2. the oral liquid that improves mucosa edema after the esophageal carcinoma radiotherapy according to claim 1, it is characterized in that various injection volume percentage ratios are respectively in the oral liquid: gentamicin sulfate injection 4%～6%, dexamethasone 3%-5%, 2% lignocaine 6%～8%, 654-2 injection 1%～2%, vitamin B
16%～8%, vitamin B
126%～8%, cimetidine 2%～4%, normal saline 64%～67%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910256132XA CN102114028A (en) | 2009-12-30 | 2009-12-30 | Oral liquid for easing mucosa edema after radiotherapy of esophageal cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910256132XA CN102114028A (en) | 2009-12-30 | 2009-12-30 | Oral liquid for easing mucosa edema after radiotherapy of esophageal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102114028A true CN102114028A (en) | 2011-07-06 |
Family
ID=44213028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910256132XA Pending CN102114028A (en) | 2009-12-30 | 2009-12-30 | Oral liquid for easing mucosa edema after radiotherapy of esophageal cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102114028A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319208A (en) * | 2011-09-23 | 2012-01-18 | 何雪心 | Suspension composition for treating oral mucositis caused by chemoradiotherapy |
| CN111467357A (en) * | 2020-04-24 | 2020-07-31 | 宋加强 | Pharmaceutical composition and preparation method and application thereof |
-
2009
- 2009-12-30 CN CN200910256132XA patent/CN102114028A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319208A (en) * | 2011-09-23 | 2012-01-18 | 何雪心 | Suspension composition for treating oral mucositis caused by chemoradiotherapy |
| CN111467357A (en) * | 2020-04-24 | 2020-07-31 | 宋加强 | Pharmaceutical composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102397277A (en) | Esomeprazole-containing medicinal composition | |
| CN101559198B (en) | Medicament for protecting joints and soft tissues | |
| CN102114028A (en) | Oral liquid for easing mucosa edema after radiotherapy of esophageal cancer | |
| CN105012487B (en) | Children's nose, which relaxes, leads to nasal drops | |
| CN109453169B (en) | Application of bulleyaconitine A | |
| CN104825778B (en) | A kind of Chinese medicine composition for being used to treat calf pneumonia | |
| CN102228660A (en) | Medicine for treating gastrointestinal diseases | |
| US11364261B2 (en) | Alleviating common cold and influenza symptoms with molecular hydrogen | |
| CN102652738A (en) | Novel medicinal outer wrapper facilitating swallow | |
| CN103933274A (en) | Traditional Chinese medicine preparation for treating periodontitis | |
| CN102349928B (en) | Combined drug for treating upper gastrointestinal tract ulcer | |
| CN101897726A (en) | Traditional Chinese medicinal powder for treating oral ulcer | |
| CN101890158A (en) | Prescription and preparation method of mixture for tonifying stomach and promoting digestion | |
| CN1248697C (en) | Medicinal composition for treating chronic enteritis and its preparing process | |
| CN101011512A (en) | Medicine for treating digestive tract tumour and its preparing process | |
| CN1297264C (en) | Loselofen sodium injection and its prepn | |
| CN103263425B (en) | Fosfomycin trometamol is preparing the application in treating chronic bacterial prostatitis medicine | |
| Chang et al. | Resolution of a vocal fold polyp treated with Chinese herbal medicine: One case report with literature review | |
| CN101129499A (en) | Shenjue anti-diarrheal plaster | |
| CN104208081A (en) | Preparation for treating oral mucositis caused by paraquat | |
| CN104771490A (en) | Traditional Chinese medicine composition for treating recurrent oral ulceration | |
| CN102247315A (en) | OTC (Over the Counter) drug frozen sucker for treating symptoms of upper respiratory tract and oral cavity and preparation method thereof | |
| CN101816795A (en) | Nanometer magnetic control throat anesthesia compound preparation and use thereof | |
| CN100364586C (en) | Medicine for treating digestive tract tumor and its preparation method | |
| CN116327746A (en) | Application of isoliquiritigenin in preparation of medicine for preventing or treating drug-induced liver injury caused by acetaminophen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110706 |